NCT00107289 2026-04-02
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
8 trialsNCT01850888 2025-12-18
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Masonic Cancer Center, University of Minnesota
Phase NA Completed
NCT00874614 2020-02-20
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 2 Unknown
NCT00126412 2019-05-31
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
GE Healthcare
Phase 3 Completed
NCT01413503 2018-09-18
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
Phase 2 Completed
NCT00028106 2017-07-02
131MIBG to Treat Malignant Pheochromocytoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00458952 2016-07-13
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT01941849 2015-12-21
VIBRaNT
University College, London
Phase 1 Withdrawn